Evaluation of Toll-like receptors expression in terms of colon cancer

Purpose of the study. To evaluate the number of cells with the CD45+/- phenotype expressing Toll-like receptors (TLRs) in tissues of the tumor, peritumoral area and resection line tissues in colon cancer (CC) with various tumor locations.Materials and methods. The study included 50 patients with CC. All patients underwent surgery as the primary treatment, and tissue material was collected from the patients. Expression of TLRs (2, 3, 4, 8, 9) on CD45+, CD45- cell populations was determined by flow cytometry in cell suspensions obtained from tissues of the tumor, peritumoral area (1–3 cm from the tumor) and resection line tissues (~10 cm from the tumor) with further calculation of the percentage of cells with the corresponding phenotype from the total number of cells.Results. An analysis of left-sided colon tumors showed lower percentage of CD45- cells expressing TLR4, 8, compared to rightsided tumors, by 38 % and 25 %. A comparative analysis of the number of CD45+ cells expressing TLR 2, 4 showed their decrease by 81 % and 87 %, respectively, compared with right-sided tumors. An assessment of the data in the perifocal zone of left-sided colon tumors, compared with right-sided ones, demonstrated a decrease in the percentage of cells with the CD45- phenotype that express TLR4, by 61 %. Resection line tissues in left-sided tumors, compared with right-sided ones, showed a statistically significant increase in the percentage of CD45- cells that express TLR 2, 4 by 205 % and 55 %, respectively. The number of CD45+ cells expressing TLR 4 decreased by 87 %. An assessment of the number of cells expressing TLRs 3 and 9 in the tumor, peritumoral area and resection line tissues did not reveal significant differences.Conclusions. Lower number of cells with CD45+ and CD45- phenotypes express TLRs 2, 4, 8 in left-sided colon tumors and their peritumoral tissues, compared to right-sided cancer.

[1]  Олег Иванович Кит,et al.  Молекулярно-генетическая классификация подтипов колоректального рака: современное состояние проблемы , 2021 .

[2]  E. Makimbetov,et al.  EPIDEMIOLOGY OF COLORECTAL CANCER , 2021, Научное обозрение. Медицинские науки (Scientific Review. Medical Sciences).

[3]  A. B. Sagakyants ОБЪЕДИНЕННЫЙ ИММУНОЛОГИЧЕСКИЙ ФОРУМ: СОВРЕМЕННЫЕ НАПРАВЛЕНИЯ РАЗВИТИЯ ФУНДАМЕНТАЛЬНОЙ И ПРИКЛАДНОЙ ОНКОИММУНОЛОГИИ (НОВОСИБИРСК, 2019) , 2020 .

[4]  О. А. Свитич,et al.  РОЛЬ ФАКТОРОВ ВРОЖДЕННОГО ИММУНИТЕТА В ПРОЦЕССЕ ОПУХОЛЕОБРАЗОВАНИЯ , 2016 .

[5]  M. Jiménez-Dalmaroni,et al.  The critical role of toll-like receptors--From microbial recognition to autoimmunity: A comprehensive review. , 2016, Autoimmunity reviews.

[6]  Ben-gang Wang,et al.  TLR3 gene polymorphisms in cancer: a systematic review and meta-analysis , 2015, Chinese journal of cancer.

[7]  Shuji Ogino,et al.  Toll-like receptor signaling in colorectal cancer: carcinogenesis to cancer therapy. , 2014, World journal of gastroenterology.

[8]  Martyn F. Symmons,et al.  Assembly and localization of Toll-like receptor signalling complexes , 2014, Nature Reviews Immunology.

[9]  B. Jenkins,et al.  Tying the knot between cytokine and toll‐like receptor signaling in gastrointestinal tract cancers , 2013, Cancer science.

[10]  A. Kalmár,et al.  Epithelial toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects. , 2013, World journal of gastroenterology.

[11]  N. Copeland,et al.  Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients , 2012, Journal of the National Cancer Institute.

[12]  R. Bloigu,et al.  Stage-dependent alterations of the serum cytokine pattern in colorectal carcinoma , 2012, British Journal of Cancer.

[13]  D. O'Leary,et al.  TLR-4 Signalling Accelerates Colon Cancer Cell Adhesion via NF-κB Mediated Transcriptional Up-Regulation of Nox-1 , 2012, PloS one.

[14]  Roberta Galli,et al.  MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response , 2012, Proceedings of the National Academy of Sciences.

[15]  R. Wolff,et al.  Toll‐like receptor genes and their association with colon and rectal cancer development and prognosis , 2012, International journal of cancer.

[16]  N. Van Rooijen,et al.  Simultaneous Targeting of Toll- and Nod-Like Receptors Induces Effective Tumor-Specific Immune Responses , 2012, Science Translational Medicine.

[17]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[18]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[19]  F. Marincola,et al.  MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18 , 2010, The Journal of experimental medicine.

[20]  Z. Qian,et al.  High expression of Toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer , 2010, British Journal of Cancer.

[21]  L. Turka,et al.  The contribution of direct TLR signaling to T cell responses , 2009, Immunologic research.

[22]  R. Xu,et al.  Innate immune signaling by Toll‐like receptor‐4 (TLR4) shapes the inflammatory microenvironment in colitis‐associated tumors , 2009, Inflammatory bowel diseases.

[23]  M. Cancro,et al.  TLR Stimulation Modifies BLyS Receptor Expression in Follicular and Marginal Zone B Cells1 , 2007, The Journal of Immunology.

[24]  D. Speiser,et al.  Human Effector CD8+ T Lymphocytes Express TLR3 as a Functional Coreceptor1 , 2006, The Journal of Immunology.